Page Title

eometryLifeSci

GeometryLifeSci has developed "GeometryFit" (1st generation) and
"GLS-Fit" (2nd generation), two proprietary molecular targeting de
novo drug design technologies to help rapidly discover small-molecule
drug candidates for treating life-threatening diseases

Develop and apply innovative knowledge-oriented,
computer-aided and structure-based de novo drug design
methodologies

Design novel small-molecule ligands for biological targets
with known 3D molecular structures

Target broad disease areas including both “Invest to Win”
areas (i.e. Cancer & Infectious diseases, etc) and
rare/neglected disease areas

What We Do

Novel - Innovative drug design leading to patentable drug
candidates

Low Cost & Green - Computer-aided de novo design reducing
high cost & waste from unnecessary synthesis & HTS by over 10 ~
20 folds

Fast - Target-to-Hit design (4 ~ 6 weeks/target), Hit-to-Lead design
(2 ~ 4 weeks/target) & drug repositioning prediction (1 ~ 2
weeks/target)

Drug-Like - Favorable PK/Toxicity (ADMET) properties
incorporated during ligand design

Easy-to-Synthesize - Synthetic tractability enforced during each
step of ligand design to avoid synthetic difficulties and cut synthesis
cost

Proven - Design technology validated on various biological targets
across different disease areas

Our Advantages